GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report)’s share price passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $26.96 and traded as low as $25.39. GENMAB A/S/S shares last traded at $25.45, with a volume of 1,711,254 shares.
GENMAB A/S/S Stock Performance
The business has a 50 day moving average price of $26.91 and a 200-day moving average price of $29.52.
About GENMAB A/S/S
Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.
Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma.
See Also
- Five stocks we like better than GENMAB A/S/S
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
